艾司西酞普兰片治疗抑郁症的Ⅱ期临床研究

被引：11

作者：

王继才

欧阳虹

李文昱

许秀峰

机构：

[1] 昆明医学院第一附属医院精神科

来源：

精神医学杂志 | 2008年 / 05期

关键词：

抑郁症; 艾司西酞普兰; 西酞普兰; 安全性;

D O I：

暂无

中图分类号：

R749.4 [情感性精神病];

学科分类号：

摘要：

目的评价艾司西酞普兰片治疗抑郁症的有效性和安全性。方法对符合《DSM-Ⅳ》抑郁症诊断标准的36例抑郁症患者进行艾司西酞普兰片和西酞普兰的对照研究,其中艾司西酞普兰片组18例(10mg/d),西酞普兰组18例(20mg/d),共治疗6周。采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、临床总体评定量表(CGI)评定临床疗效,不良事件量表(AE)评定安全性。结果经6周治疗后,艾司西酞普兰组治疗总有效率为88.9%,西酞普兰组为75.0%,两组比较差异无显著性(P>0.05)。两组HAMD、HAMA评分治疗前后差异有高度显著性(P<0.001)。两组药物不良反应的发生率无显著性差异(P>0.05),常见的不良反应有恶心、口干、头昏等。结论艾司西酞普兰片治疗抑郁症疗效好,不良反应少而轻,适合临床应用。

引用

页码：330 / 333

页数：4

共 20 条

[1] Arandomized study compar-ing escitalopramwith venlafaxine XRin primary care patients with ma-jor depressive disorder. Montgomery SA,HuusomAKT,Bothmer J. Neuropsychobiology . 2004
[2] Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities[J] . C. Sánchez,P. B. F. Bergqvist,L. T. Brennum,S. Gupta,S. Hogg,A. Larsen,O. Wiborg. &nbspPsychopharmacology . 2003 (4)
[3] Escitalo- pram,the S-(+)-enantiomer of citalopram,is a selective seroto- nin reuptake inhibitor with potent effects in animal models predic- tive of antidepressant and anxiolytic activities. SANCHEZ C,BERGQVIST PB,BRENNUM LT,et al. Psychopharma- cology(Berl) . 2003
[4] R-citalopramattenuates anxiolytic effects of escitalopramin arat ultrasonic vocalization model. Sanchez C. European Journal of Pharmacology . 2003
[5] Efficacy of escita- lopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and ven- lafaxine XR:a meta-analysis. KENNEDY SH,ANDERSEN HF,LAM RW. Psychiatry Neurosci . 2006
[6] Escitalopram in the treatment of depressed elderly patients. Kasper,S,de,Swart,H,Andersen,HF. American Journal of Geriatric Psychiatry . 2005
[7] Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. Davidson JR,Bose A,Wang Q. Journal of Clinical Psychopharmacology . 2005
[8] Evaluation of the cost effec-tiveness of escitalopramversus venlafaxine XRin major depressive dis-order. Fernandez JL,Montgomery S,Francois C. Pharmacoeconomics . 2005
[9] Escitalopram (10-20mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Lepola UM,Loft H,Reines EH. International Clinical Psychopharmacology . 2003
[10] Escitalopram in the long-term treatment of major depressive disorder. Wade A. Annals of Clinical Psychiatry . 2006

← 1 2 →